Trials / Recruiting
RecruitingNCT07454382
A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
Phase 2 Trial of Elranatamab With Cyclophosphamide in Relapsed/Refractory Multiple Myeloma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether the combination of elranatamab and cyclophosphamide is an effective treatment for people with relapsed/refractory multiple myeloma (MM) who have risk factors that may affect how well their disease would respond to elranatamab alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Elranatamab-bcmm | Elranatamab-bcmm is a recombinant, humanized, bispecific IgG2 kappa antibody |
| DRUG | Cyclophosphamide | Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen mustards |
Timeline
- Start date
- 2026-02-27
- Primary completion
- 2029-08-27
- Completion
- 2029-08-27
- First posted
- 2026-03-06
- Last updated
- 2026-03-06
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07454382. Inclusion in this directory is not an endorsement.